# Astrocyte-induced cortical vasodilation is mediated by D-serine and endothelial nitric oxide synthase

Jillian L. LeMaistre Stobart<sup>a,b,1</sup>, Lingling Lu<sup>a,b,1</sup>, Hope D. I. Anderson<sup>c,d</sup>, Hisashi Mori<sup>e</sup>, and Christopher M. Anderson<sup>a,b,2</sup>

<sup>a</sup>Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, MB, Canada R3E 0T6; <sup>b</sup>Division of Neurodegenerative Disorders, St. Boniface Hospital Research, Winnipeg, MB, Canada R2H 2A6; <sup>c</sup>Faculty of Pharmacy, University of Manitoba, Winnipeg, MB, Canada R3E 0T5; <sup>d</sup>Canadian Centre for Agri-Food Research in Health and Medicine, St. Boniface Hospital Research, Winnipeg, MB, Canada R2H 2A6; and <sup>e</sup>Department of Molecular Neuroscience, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan

Edited by Solomon H. Snyder, The Johns Hopkins University School of Medicine, Baltimore, MD, and approved January 11, 2013 (received for review September 14, 2012)

Astrocytes play a critical role in neurovascular coupling by providing a physical linkage from synapses to arterioles and releasing vaso-active gliotransmitters. We identified a gliotransmitter pathway by which astrocytes influence arteriole lumen diameter. Astrocytes synthesize and release NMDA receptor coagonist, D-serine, in response to neurotransmitter input. Mouse cortical slice astrocyte activation by metabotropic glutamate receptors or photolysis of caged Ca<sup>2+</sup> produced dilation of penetrating arterioles in a manner attenuated by scavenging D-serine with D-amino acid oxidase, deleting the enzyme responsible for D-serine synthesis (serine racemase) or blocking NMDA receptor glycine coagonist sites with 5,7dichlorokynurenic acid. We also found that dilatory responses were dramatically reduced by inhibition or elimination of endothelial nitric oxide synthase and that the vasodilatory effect of endothelial nitric oxide synthase is likely mediated by suppressing levels of the vasoconstrictor arachidonic acid metabolite, 20-hydroxy arachidonic acid. Our results provide evidence that p-serine coactivation of NMDA receptors and endothelial nitric oxide synthase is involved in astrocyte-mediated neurovascular coupling.

# two-photon | functional hyperemia | $Ca^{2+}$ uncaging

erebral blood flow is regulated by autoregulation, which maintains constant flow during changes in systemic blood pressure, and functional hyperemia, which refers to matched increases in blood flow to brain areas with high neuronal energy demand. Intracerebral arterioles and capillaries account for 30-40% of total cerebrovascular blood flow resistance (1), and therefore, changes to the diameter of small penetrating cortical vessels result in significant changes in local cerebral blood flow. Astrocytes have endfeet directly apposed to these resistance vessels and are critical regulators of arteriole lumen diameter. Astrocyte endfeet express Ca<sup>2+</sup>-activated K<sup>+</sup> channels that gate vasodilatory K<sup>+</sup> efflux in response to glutamatergic input (2, 3). Glutamate neurotransmission also causes Ca<sup>2+</sup>-dependent arachidonic acid (AA) metabolism and release of vasodilatory AA metabolites from astrocytes, including prostaglandin  $E_2$  (PGE<sub>2</sub>), produced by cyclooxygenase (COX), and epoxyeicosatrienoic acids (EETs), produced by cytochrome P450 epoxygenase (4-8). Astrocytederived AA can also be metabolized by cytochrome P450 w-hydroxylase to the vasoconstrictor, 20-hydroxyeicosatetranoic acid (20-HETE) (4, 6-8). Ambient tissue oxygen levels dictate whether astrocytes produce AA-dependent vasodilation or vasoconstriction in brain slices and isolated retina (6, 7). Production of 20-HETE is preferred at high pO<sub>2</sub> (95% O<sub>2</sub> in solution) (6–8), whereas  $pO_2$  closer to physiologic levels (20%) O<sub>2</sub>) inhibits prostaglandin-lactate transporter activity, producing high extracellular  $PGE_2$  levels (7) and reduced 20-HETE synthesis (6).

Application of glutamate or NMDA directly to the brain surface dilates pial arteries (9, 10) by a mechanism mediated by NMDA receptors (9–12) and neuronal nitric oxide synthase (nNOS) (13–15). Although NO is capable of increasing lumen diameter by directly affecting smooth muscle, it may also trigger vasodilation at physiologic  $pO_2$  by reducing  $\omega$ -hydroxylase activity and 20-HETE production, thereby shifting the balance of constrictor and dilator AA metabolites derived from astrocytes (4, 16, 17). In vivo, it was suggested NO derived from nNOS, specifically, reduces 20-HETE levels (17), but there is no further evidence of a specific link between nNOS and astrocyte AA metabolism in neurovascular coupling. Endothelial NOS (eNOS) plays a role in baseline brain vascular tone and pathological hyperemia (13, 18– 21), but there has not yet been a connection made between eNOS, astrocyte function, and hyperemic vasodilation.

NMDA receptors are activated by binding of glutamate and a coagonist that binds to a strychnine-insensitive glycine regulatory site (22). D-Serine is more effective than glycine as an NMDA receptor coagonist (23-25) and has a brain distribution that closely parallels that of NMDA receptors (26). In addition, D-serine is extensively distributed in glial cells (26, 27), is released as a gliotransmitter by Ca<sup>2+</sup>-dependent exocytosis in response to glutamatergic input (28), and contributes to astrocyteneuron communication (29-31). Given the established role of NMDA receptors in hyperemic blood flow regulation, we hypothesized that astrocyte D-serine is directly involved in regulating the lumen diameter of brain resistance vessels. We showed previously that isolated middle cerebral arteries dilated in response to exogenous glutamate and D-serine treatment by an NMDA receptor-mediated mechanism (32). The goal of the current study was to determine whether endogenous D-serine is involved in astrocyte-mediated neurovascular coupling in cortical penetrating arterioles. We demonstrated that endogenous Dserine contributes to the vasodilatory response produced by direct astrocyte activation. We also provide evidence that NMDA receptors and eNOS are involved in this response, identifying a signal linking astrocytes and eNOS-mediated vasodilation.

## Results

Metabotropic Glutamate Receptor Activation Causes D-Serine–Mediated Dilation of Cortical Arterioles. Immunohistochemistry in fixed cortical slices revealed D-serine immunoreactivity in astrocyte endfeet apposed to penetrating arterioles (Fig. 1). D-Serine signal (Fig. 1*A*) was detected in cells coexpressing the astrocyte marker, GFAP (Fig. 1*B*), around arterioles labeled with isolectin B<sub>4</sub> (Fig. 1*C*). This suggests there is a D-serine pool in close proximity to cortical supply vessels. Separately, the metabotropic glutamate receptor (mGluR) agonist, ( $\pm$ )-1-aminocyclopentane-*trans*-

<sup>2</sup>To whom correspondence should be addressed. E-mail: chris.anderson@med.umanitoba.ca.

Author contributions: H.D.I.A. and C.M.A. designed research; J.L.S. and L.L. performed research; H.M. contributed new reagents/analytic tools; J.L.S., L.L., H.D.I.A., and C.M.A. analyzed data; and J.L.S. and L.L. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

<sup>&</sup>lt;sup>1</sup>J.L.S. and L.L. contributed equally to this work.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. 1073/pnas.1215929110/-/DCSupplemental.



**Fig. 1.** D-serine localization to perivascular astrocyte endfeet in fixed cortical slices. (*A*–*D*) D-serine immunoreactivity (*A*, red) was localized to perivascular sites colabeled with the astrocyte marker, GFAP (*B*, green) in glutaraldehyde-fixed cortical slices (30 µm) from 14–19-d-old mice. Cerebrovasculature was labeled with isolectin B<sub>4</sub> (*C*, blue). (*D*), Overlay of *A*–*C* (scale bar, 20 µm). (*E*) mGluR agonist tACPD (100 µM) induced significant release of D-serine from brain slices compared with untreated controls. Detection was eliminated by coexposure to DAAO (0.1 Units/mL). Data are mean ± SEM; \*\**P* < 0.0.01 for tACPD compared with control; †*P* < 0.01 for tACPD/TTX compared with control using two-way ANOVA with Bonferroni post hoc test.

1,3-dicarboxylic acid (*t*ACPD), has been shown to increase intracellular astrocyte Ca<sup>2+</sup> levels and dilate local arterioles (7, 33), as well as stimulate D-serine release in a Ca<sup>2+</sup> and SNAREprotein-dependent manner (28, 34). We confirmed that *t*ACPD treatment of acute cortical slices (100  $\mu$ M) stimulated significant accumulation of extracellular D-serine after 15 min of exposure using a bulk chemiluminescence assay (Fig. 1*E*). Pretreatment with the D-serine catabolic enzyme, D-amino acid oxidase (DAAO), significantly reduced extracellular D-serine accumulation, indicating specific detection of D-serine. Tetrodotoxin (TTX) pretreatment had no effect, suggesting neuronal Dserine pools accessible by depolarization (35) are not involved in this response.

We exposed cortical slices to tACPD and simultaneously monitored perivascular astrocyte  $Ca^{2+}$  and neighboring arteriole diameter in real time using two-photon laser scanning microscopy (Fig. 2A-C). In slices maintained in artificial cerebrospinal fluid (aCSF) with 20% O<sub>2</sub>, tACPD enhanced rhodamine-2 fluorescence in astrocytes in a manner temporally associated with dilatory responses in cortical arterioles (Fig. 2D). tACPD produced a maximal lumen diameter increase of  $3.7 \pm 0.1\%$ , 75 s after exposure (Fig. 2E; maximal of  $4.1 \pm 0.8\%$  without fixing the time point). Dilatory responses were assessed as area under the curve (AUC) between time 0 (tACPD addition) and return to baseline (Fig. 2E). Preincubation of slices with DAAO (0.1 units/ mL) significantly reduced vasodilation (Fig. 2F), whereas addition of exogenous D-serine to compete for DAAO activity restored vasodilatory responses. tACPD-induced vasodilation in cortical slices isolated from mice lacking the D-serine synthesis enzyme, serine racemase (SR) was dramatically reduced, further indicating an important role for D-serine (Fig. 2G). These experiments demonstrate that perivascular astrocytes contain Dserine that can be released in quantities sufficient to increase arteriolar lumen diameter in glutamatergic neurotransmission simulated by mGluR activation. TTX pretreatment did not affect vasodilatory responses (Fig. 2H), arguing against an effect of D-serine derived from neuronal stores accessed by depolarization.

Direct Astrocyte Activation Causes p-Serine-Dependent Dilation of **Cortical Arterioles.** To directly link astrocyte Ca<sup>2+</sup> elevations with vasodilatory responses, we stimulated increases in cytoplasmic Ca<sup>2+</sup> levels of single rhodamine-2-labeled perivascular astrocytes using flash photolysis of the caged Ca<sup>2+</sup> compound, o-nitrophenyl-EGTA AM (NP-EGTA; Fig. S1). Astrocyte Ca<sup>2+</sup> (rhodamine-2) and arteriole diameter were subsequently monitored (Fig. 3 A-C). Astrocyte Ca<sup>2+</sup> increases consistently correlated with dilation of neighboring cortical arterioles (Fig. 3D, representative experiment). Average vasodilation peaked at 5.7 +0.2%, 105 s after stimulation (Fig. 3B;  $7.0 \pm 0.9\%$  without fixing the time point). DAAO significantly reduced vasodilation in a manner reversed by addition of exogenous D-serine after flash photolysis (Fig. 3F). Similarly, vasodilation was significantly inhibited by deletion of SR (Fig. 3G). These data demonstrate that endogenous D-serine plays a role in cortical vasodilation resulting from direct activation of a single perivascular astrocyte by  $Ca^{2+}$  uncaging. TTX (1  $\mu$ M) did not significantly alter



**Fig. 2.** tACPD induces D-serine–dependent cortical vasodilation. Bath application of tACPD (100  $\mu$ M) elevated astrocyte Ca<sup>2+</sup> (green, Rhod 2) and triggered arteriolar (red, isolectin B<sub>4</sub>) vasodilation in a temporally correlated manner. (*A*–C) Representative images for a single astrocyte–arteriole pair before tACPD addition (*A*) and 5 (*B*) and 45 (C) s after (scale bar, 15  $\mu$ m). (*D*) Representative plot of changes in astrocyte Ca<sup>2+</sup> (blue) and arteriole diameter (red) after tACPD treatment. (*E*) Plot of average dilation of 15 vessels after tACPD treatment over 300 s. Data are mean  $\pm$  SEM. (*F*), DAAO significantly inhibited vasodilation of arterioles after tACPD application, whereas exogenous D-serine (100  $\mu$ M) with DAAO recovered the dilatory effect of tACPD. (*G*) Genetic deletion of SR (SR<sup>-/-</sup>) eliminated the vasodilation. For *G* and *H*, data are mean  $\pm$  SEM of total AUC for individual plots of percent relaxation versus time. \*\**P* < 0.01 using one-way ANOVA with Student Newman–Keuls test (>2 groups) or *t* tests (2 groups).



Fig. 3. Direct astrocyte Ca<sup>2+</sup> uncaging leads to D-serine-dependent cortical vasodilation. Flash photolysis of o-nitrophenyl-EGTA in perivascular astrocyte endfeet stimulated elevation of local Ca2+ levels (green, Rhod 2) in a manner that temporally corresponded with an increase in lumen diameter of a neighboring arteriole (red, isolectin  $B_4$ ). (A–C) Representative images of a single perivascular astrocyte and arteriole are shown before (A) and after (B and C) flash photolysis (scale bar, 15 µm). (D) Representative plot of changes in astrocyte Ca<sup>2+</sup> (blue) and arteriole diameter (red) after photolysis. (E) Plot of average dilation of 21 vessels after astrocyte Ca<sup>2+</sup> uncaging over 300 s. Data are mean ± SEM. (F) DAAO (0.1 Units/mL) significantly inhibited vasodilation induced by direct astrocyte activation, whereas exogenous D-serine (100  $\mu$ M) with DAAO recovered the dilatory effect. (G) Genetic deletion of SR (SR-/-) eliminated the vasodilatory response to astrocyte Ca2+ uncaging. (H) TTX (1 µM) did not affect vasodilation induced by astrocyte Ca<sup>2+</sup> uncaging. For G and H, data are mean  $\pm$  SEM of total AUC for individual plots of percent relaxation versus time. \*P < 0.05, \*\*P < 0.01 using one-way ANOVA with Student Newman–Keuls test (>2 groups) or t tests (2 groups).

vasodilatory responses (Fig. 3*H*), suggesting neuronal excitation is not necessary for direct astrocyte-mediated vasodilation.

**D-Serine–Dependent Vasodilation Is Dependent on Glutamate Corelease** and NMDA Receptors. Cortical slices were exposed to the NMDA receptor competitive glycine/D-serine coagonist site antagonist 5,7-dichlorokynurenic acid (DCKA; 100 µM) or the competitive glutamate-site antagonist 2-amino-5-phosphonopentanoate (AP5; 50  $\mu$ M), before flash photolysis of caged Ca<sup>2+</sup>. Both DCKA and AP5 significantly reduced vasodilatory responses (Fig. 4A). Preincubation of cortical slices with glutamate dehydrogenase (GDH; 1 U/mL) also attenuated arteriole dilation resulting from flash photolysis (Fig. 4B), indicating that both glutamate and D-serine (Figs. 2 and 3) are involved in astrocytemediated vasodilation. In agreement, tACPD caused TTX-independent bulk release of endogenous glutamate from cortical slices (Fig. 4C), supporting the idea that glutamate and D-serine are coreleased from astrocytes and play a joint role in neurovascular coupling.

Astrocyte-Mediated Vasodilation Is Dependent on  $PGE_2$  and eNOS. Our data demonstrate that intact endothelium and eNOS are required for D-serine and glutamate to increase lumen diameter in isolated middle cerebral arteries (32). We thus tested the

Stobart et al.

hypothesis that D-serine and glutamate-induced vasodilation in cortical slice arterioles is mediated by eNOS. In response to astrocyte Ca<sup>2+</sup> uncaging, genetic deletion of eNOS dramatically attenuated increases in lumen diameter compared with treatment controls (Fig. 5*A*). We also measured vasodilatory responses to an exogenous glutamate and D-serine mixture (10  $\mu$ M each with 1  $\mu$ M TTX) in the presence and absence of the eNOS inhibitor, N5-(1-iminoethyl)-L-ornithine (L-NIO; 3  $\mu$ M). L-NIO significantly reduced arteriole dilation by glutamate and D-serine (Fig. 5*B*), directly linking D-serine with eNOS activity and vasodilation in cortical slices.

Several studies have demonstrated that astrocyte-induced cortical vasodilation is mediated by COX-dependent metabolism of AA to PGE<sub>2</sub> (5, 7, 33). We therefore tested for PGE<sub>2</sub> involvement in our model by using indomethacin (INM; 100  $\mu$ M) to inhibit COX. INM alone reduced vasodilation produced by astrocyte Ca<sup>2+</sup> uncaging by 87% (Fig. 5*C*). This is not significantly different from the L-NIO-mediated reduction (55%). Combined, INM and L-NIO significantly enhanced the effect of L-NIO alone, producing vasoconstriction in response to astrocyte Ca<sup>2+</sup> uncaging (Fig. 5*C*). *t*ACPD-induced astrocyte activation increased PGE<sub>2</sub> levels in a manner independent of L-NIO or genetic eNOS elimination (Fig. 5*D*), indicating that eNOS does not cause vasodilation by directly influencing PGE<sub>2</sub>.

eNOS Causes Vasodilation by Suppressing 20-HETE Production. There is substantial evidence that NO inhibits production of the vasoconstrictor AA metabolite 20-HETE (36), leading to vasodilation in brain microvasculature (4, 17), but any contribution of eNOS to this pathway is yet to be identified. In our hands, brain slice production of 20-HETE in the presence of *t*ACPD was significantly enhanced in eNOS-null cortical slices (Fig. 6A), demonstrating that eNOS activity suppresses 20-HETE production in this model. To determine whether suppression of 20-HETE participates in eNOS-mediated vasodilation, we examined the effect of eNOS inhibition by L-NIO in the absence of a functional 20-HETE production pathway, suppressed by the



**Fig. 4.** Cortical vasodilation by D-serine is dependent on glutamate and NMDA receptors. (*A*) tACPD induced significant TTX-insensitive (1  $\mu$ M) glutamate release, relative to control cortical slices (\*P < 0.05 using two-way ANOVA with Bonferroni test). (*B*) GDH (1 U/mL) significantly reduced arteriole vasodilation induced by astrocyte Ca<sup>2+</sup> uncaging (\*\*P < 0.001, *t* test). (*C*) Competitive NMDA receptor antagonists DCKA (glycine site, 100  $\mu$ M) and AP5 (glutamate site, 50  $\mu$ M) significantly blocked arteriole vasodilation induced by direct astrocyte Ca<sup>2+</sup> uncaging (\*P < 0.05; \*\*P < 0.01, one-way ANOVA with Student Newman–Keuls test). All data are mean  $\pm$  SEM.



**Fig. 5.** Astrocyte-induced cortical vasodilation is mediated by PGE<sub>2</sub> and eNOS. (*A*) eNOS-null mice displayed reduced cortical vasodilatory efficacy in response to astrocyte Ca<sup>2+</sup> uncaging compared with C57 wild-type mice (\*\**P* < 0.01, *t* test). (*B*) Coapplication of glutamate (10  $\mu$ M), D-serine (10  $\mu$ M), and TTX (1  $\mu$ M) produced cortical slice vasodilation sensitive to inhibition by the eNOS selective antagonist L-NIO (3  $\mu$ M, \*\**P* < 0.01, *t* test). (*C*) Both the COX inhibitor INM (100  $\mu$ M) and eNOS inhibitor L-NIO (3  $\mu$ M) significantly reduced vasodilation in response to astrocyte Ca<sup>2+</sup> uncaging. Combined INM and L-NIO caused significant vasoconstriction in response to astrocyte Ca<sup>2+</sup> uncaging (\**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001 using one-way ANOVA with Student Newman–Keuls test). (*D*) PGE<sub>2</sub> release from cortical slices was measured by ELISA 5 min after tACPD treatment and was not significantly affected by treatment with L-NIO (3  $\mu$ M) or genetic eNOS deletion (ns, *P* > 0.05 using one-way ANOVA with Student Newman–Keuls test). All data are mean  $\pm$  SEM.

CYP4A ( $\omega$ -hydroxylase) inhibitor *N*-hydroxy-N'-(4-n-butyl-2methylphenyl)formamidine (HET0016; 100 nM). Vasodilation induced by astrocyte Ca<sup>2+</sup> uncaging was significantly inhibited by L-NIO alone but not in combination with HET0016 (Fig. 6*B*), suggesting that eNOS vasodilation is dependent on activity of the 20-HETE pathway.

Here, we provided evidence that endogenous D-serine is a me-

diator of neurovascular coupling. D-Serine was responsible for

### Discussion

t-ACPD

L-NIO

eNOS

astrocyte-induced dilation of penetrating cortical arterioles in  $A^{200}_{\frac{p}{2}150} \qquad B^{1500}_{\frac{p}{2}150} \qquad B^{1500}_{\frac{p}{2}1500} \qquad B^{1500}_{\frac{p}{2}1500}$ 



Uncaging

HET

L-NIC

+ +

+

**Fig. 6.** eNOS inhibits 20-HETE production. (*A*) Cortical slice 20-HETE production in response to tACPD was statistically unchanged by L-NIO (ns, *P* > 0.05) and increased by eNOS deletion (\*\**P* < 0.01, one-way ANOVA with Student Newman–Keuls test). (*B*) Alone, L-NIO (3  $\mu$ M) significantly reduced cortical vasodilation induced by astrocyte Ca<sup>2+</sup> uncaging (\**P* < 0.05, one-way ANOVA with Student Newman–Keuls test). This effect was lost in the presence of HET0016 (HET, 100 nM; ns, *P* > 0.05), which interferes with 20-HETE formation. All data are mean  $\pm$  SEM.

+ +

+

a manner dependent on coavailability of extracellular glutamate and NMDA receptors. We also demonstrated that astrocytemediated cortical vasodilation is at least partially dependent on eNOS-derived suppression of 20-HETE.

Several lines of evidence support involvement of astrocyte D-serine in dilation of penetrating cortical arterioles in brain slices. D-Serine immunoreactivity was identified in perivascular astrocyte endfeet, in agreement with a previous report (26). Also consistent with published data (28), we found that simulating glutamatergic neurotransmission by exposing cortical slices to tACPD caused significant efflux of D-serine into the bathing medium (28). These data together suggest there is a source of D-serine available for regulated release at the neurovascular unit. We then showed that DAAO and SR deletion significantly inhibited dilation of brain slice-penetrating cortical arterioles induced by tACPD. This observation established a critical role for endogenous D-serine in regulating brain vascular lumen diameter, and this role is supported further by the demonstration that vasodilatory effects were mitigated by interfering with specific binding for D-serine in the NMDA receptor complex by DCKA. Because tACPD activates both neuronal and astrocytic mGluRs, we considered the possibility that the vasodilatory effect of D-serine is independent of astrocyte activation by tACPD. Although the failure of TTX to suppress D-serine release and cortical vasodilation argues against this idea, we more precisely ascertained the role of astrocytes in D-serine-mediated vasodilation by using flash photolysis of caged Ca<sup>2+</sup> (NP-EGTA) in perivascular astrocyte endfeet. Direct astrocyte activation was sufficient to increase arteriolar lumen diameter in cortical slices. Moreover, uncaging-induced vasodilation was blocked by more than 88% by DAAO and 72% by SR deletion, providing further support for a vasodilatory pathway originating with glutamate neurotransmission and leading to astrocyte Ca2+ elevation, D-serine release from astrocytes, and vascular smooth muscle relaxation.

The impact of observed changes to the lumen diameter on blood flow is an important consideration. Poiseuille's Law dictates that resistance to blood flow decreases as a function of the fourth power of any increases in lumen diameter. Therefore, a 7% increase in lumen diameter (average achievement with uncaging) reduces resistance by a more impressive magnitude of 24%. In addition, comparisons across experimental conditions are critical because some models use preconstriction paradigms to achieve a much higher magnitude of vasodilation (33, 37). Our observations are consistent with vasodilation magnitudes observed by another group using brain slices maintained without preconstriction at equal aCSF oxygenation (7). These points, coupled with observations that vasodilation in vitro likely underestimates COX-mediated vasodilation seen in pressurized vessels in vivo (5), support speculation that our observed vasodilatory magnitudes in vitro translate into meaningful blood flow changes in vivo.

Our data support a vasodilatory mechanism of D-serine mediated by coactivation of NMDA receptors with glutamate. Again, cortical vasodilation induced by astrocyte Ca<sup>2</sup> <sup>-</sup> uncaging was significantly attenuated by DCKA, directly indicating that activation of NMDA receptor glycine sites is involved. Importantly, this effect was also inhibited by AP5, indicating that occupation of the NMDA receptor glutamate binding site is also required for vasodilation in this paradigm. Paired involvement of glutamate and D-serine is further supported by our observations that tACPD stimulated both glutamate and D-serine release (Figs. 4C and 1E, respectively) and that the presence of the glutamate catabolic enzyme GDH eliminated cortical vasodilation initiated by Ca<sup>2+</sup> uncaging. Overall, these results show that both coagonists of NMDA receptors are required for a significant component of astrocyte-induced vasodilation in cortical slices. There is a report that AP5 does not affect cortical vasodilation in response to tACPD (33). Although this is seemingly

inconsistent with our results, Zonta et al. (33) used artificial CSF equilibrated with 95% O2, which is a condition that is dramatically different from ours (20%) and favors production of the smooth muscle constrictor 20-HETE (4, 6, 7). This may mask the vasodilatory effects of D-serine and NMDA receptors, making the models difficult to compare appropriately. The cellular source of NMDA receptors responsible for vasodilation in our model is not clear. Our previous work indicates that brain arterial endothelial cells express NMDA receptors capable of initiating a vasodilatory response to extraluminally applied glutamate and D-serine (32). Current data indicate that eNOS contributes to astrocyte-mediated vasodilation and that TTX-sensitive neuronal Na<sup>+</sup> channels, and therefore direct vessel innervation (38), are not required for vasodilation downstream of astrocyte activation. All of these observations tempt speculation that endothelial, rather than neuronal, NMDA receptors participate in astrocyte-mediated vasodilation, but definitive experiments have yet to be performed.

A clear conclusion drawn from our current findings is that eNOS participates in astrocyte-mediated dilation of penetrating cortical arterioles. NO is central to NMDA receptor-mediated neurovascular coupling (10, 39, 40), but only a role for nNOS, specifically, has been described (14, 39, 41). Our finding that a mixture of glutamate or NMDA and D-serine can dilate isolated cerebral arteries by an endothelium and eNOS-dependent mechanism (32) gave rise to the hypothesis that eNOS may be involved in vasodilation initiated by astrocyte gliotransmission in situ. In support of this hypothesis, cortical vasodilation induced by astrocyte Ca<sup>2+</sup> uncaging was significantly inhibited by L-NIO at a concentration  $(3 \ \mu M)$  yielding strong selectivity for eNOS (42, 43) and by genetic eNOS deletion. D-serine was also linked directly to eNOS activity in cortical slice arterioles, as L-NIO inhibited vasodilation induced by exogenous application of glutamate/D-serine (10 µM each) in the presence of TTX. In functional hyperemia in vivo, a recent cat study concluded that both nNOS and eNOS participate in vasodilatory responses, with eNOS becoming more prominent at lower levels of neuronal activity and nNOS dominating at higher neuronal activation levels (44). We did not compare the relative roles of eNOS and nNOS in cortical vasodilation induced by tACPD or direct astrocyte activation. Further studies targeting eNOS and nNOS loss of function will assist in determining the relative roles of these isoforms and the cell types in which they are expressed.

Our tACPD and astrocyte  $Ca^{2+}$  uncaging paradigms closely resemble those used in several previous studies demonstrating the astrocyte-mediated cortical or hippocampal vasodilation is mediated by the COX metabolite  $PGE_2$  (5–7, 33). Therefore, it is important to address how discovery of a role for eNOS fits with the established COX-mediated mechanism. We found agreement with previous studies (5–7) by showing that COX metabolites also contributed to astrocyte-mediated vasodilation, as INM inhibited vascular responses to Ca<sup>2+</sup> uncaging. Addition of INM to L-NIO treatment resulted in a loss of vasodilatory effect greater than that achieved with L-NIO alone and actually produced smooth muscle constriction, suggesting that eNOS and COX pathways are additive. Additivity is further supported by the observation that astrocyte-activated eNOS has no direct effect on  $PGE_2$  levels (Fig. 5C). It has been reported that NO modulates the vascular effects of AA metabolites by inhibiting cytochrome P450 enzymes that produce 20-HETE and EETs (4). In our hands, cortical 20-HETE content in response to tACPD treatment was significantly enhanced in eNOS-/- slices. This demonstrates that eNOS-derived NO inhibits 20-HETE production and suggests that vasodilation may result from NO-induced suppression of the 20-HETE influence on smooth muscle tone. Support for functional suppression of the vascular effects of 20-HETE comes from experiments using L-NIO and an inhibitor of CYP4A w-hydroxylase (HET0016), which is the enzyme

responsible for 20-HETE formation. The ability of L-NIO to attenuate vasodilatory responses to astrocyte  $Ca^{2+}$  uncaging was lost in the presence of HET0016, suggesting that the vasodilatory role of eNOS-derived NO depends on an active 20-HETE production pathway. Overall, our data support dual astrocyte-mediated vasodilatory mechanisms working together. We and others demonstrated that astrocyte activation leads to direct COX-dependent, PGE<sub>2</sub>-mediated increases in cortical arteriole lumen diameter. Our data support the idea that astrocyte activation also leads to eNOS activity and suppression of 20-HETE levels, thus facilitating the direct PGE<sub>2</sub>-mediated vasodilation.

### **Materials and Methods**

**Chemicals and Animals.** All chemicals were purchased from Sigma-Aldrich, unless otherwise noted. Animal procedures were approved by the Office of Research Ethics and Compliance Animal Care Committee for the Bannatyne Campus, University of Manitoba. SR deletion mice were generated from C57BL/6-derived embryonic stem cells transfected with the gene-targeting vector containing C57BL/6 mouse genomic DNA and were expanded by crossing with C57BL/6 mice (45). Wild-type littermate controls were used for experiments comparing control to SR knockout phenotypes. eNOS deletion mice were purchased from Jackson Laboratories and bred at the R.O. Burrell Lab at St. Boniface Hospital Research. C57BL/6 was used as the control strain.

Brain Slice Preparation and Two-Photon Laser Scanning Microscopy. Brains from CD1 or C57BL/6 mice (14–19 d old) were placed in ice-cold cutting buffer (2.5 mM KCl, 1.25 mM NaH<sub>2</sub>PO<sub>4</sub>, 10 mM MgSO<sub>4</sub>, 5 mM CaCl<sub>2</sub>, 26 mM NaHCO3, 10 mM glucose, 230 mM sucrose) bubbled with 95%  $\mathrm{O}_2$  and 5%  $CO_2$ . Slices were cut on a vibrating blade microtome (350  $\mu$ m) and were then maintained in aCSF (126 mM NaCl, 2.5 mM KCl, 1.25 mM NaH<sub>2</sub>PO<sub>4</sub>, 2 mM MgCl<sub>2</sub>, 2 mM CaCl<sub>2</sub>, 26 mM NaHCO<sub>3</sub>, 10 mM glucose) equilibrated with 95% O<sub>2</sub>, 5% CO<sub>2</sub>, and heated to 35 °C. After 1 h, slices were loaded with the Ca<sup>2+</sup> indicator dye, Rhodamine-2 AM (10 µM; Invitrogen), and Griffonia simplicifolia 1 Isolectin B<sub>4</sub> tagged with Alexa Fluor 488 (5 µg/mL; Invitrogen). Two-photon imaging proceeded on the stage of an upright microscope in aCSF equilibrated with 20% O2, 5% CO2, and 75% N2. Scans were performed using an excitation wavelength of 800 nm, delivered through an Ultima multiphoton scanhead, with dual galvanometers for imaging and uncaging (Prairie Technologies), by a pulsed Ti-sapphire laser (Coherent Inc.). For astrocyte Ca<sup>2+</sup> uncaging, cortical slices were incubated with o-nitrophenyl-EGTA AM (10  $\mu M;$  Invitrogen) for 1 h. Cytoplasmic photoliberation of  $Ca^{2+}$ was achieved using functional mapping software (TriggerSync, Prairie Technologies) to guide a 700 nm/100 ms laser pulse through a voltagecontrolled pockels cell. Images were analyzed every 15 s using PrairieView software to determine vessel lumen diameter, as marked by isolectin staining. Changes in vessel lumen diameter were correlated with astrocyte rhodamine-2 Ca<sup>2+</sup> fluorescence intensity changes, which were measured using ImageJ.

**p-Serine and Glutamate Release Assays.** Acute brain slices were incubated in aCSF equilibrated with 20% O<sub>2</sub>/5% CO<sub>2</sub> and then stimulated with tACPD (100  $\mu$ M) for 15 min. Some slices were pretreated with DAAO (0.1 U/mL) or TTX (1  $\mu$ M) for 20 min. During tACPD stimulation, samples of aCSF were collected at 0 min, 5 min, or 15 min for measurement of p-serine and glutamate concentrations. p-serine release was measured by chemiluminescent assay, as described previously with minor modification (46, 47). We mixed 10  $\mu$ l of each sample with 100  $\mu$ l of aCSF containing 100 mM Tris-HCI, pH 8.8, 20 U/mL peroxidase, and 8  $\mu$ l of luminol. Samples were incubated 15 min to decrease background signal of luminol, and then 10  $\mu$ l of DAAO (75 U/mL) was added, where applicable. Chemiluminescence kinetics was recorded for 5 min at room temperature using a TD-20/20 Luminometer (Turner Designs). p-serine concentrations were calculated based on a standard curve. Glutamate release was determined at each time point by using Amplex Red Glutamic Acid/Glutamate Oxidase Assay Kit (Invitrogen).

**PGE<sub>2</sub> and 20-HETE ELISAs.** Acute brain slices were incubated in aCSF equilibrated with 20% O<sub>2</sub>/5% CO<sub>2</sub> and stimulated with *t*ACPD (100  $\mu$ M) for 5 min. Some slices were pretreated with TTX (1  $\mu$ M) with or without L-NIO (3  $\mu$ M) for 20 min. PGE<sub>2</sub> release in aCSF was measured using the PGE<sub>2</sub> enzyme immunoassay (EIA) Kit (Cayman). For 20-HETE, brain slices were lysed and 20-HETE production was measured by 20-HETE ELISA Kit (Detroit R&D, Inc.).

**p-Serine Immunohistochemistry.** p-serine immunostaining was modified from the procedure by Schell et al. (1995) (26). Brains from 14–19-d-old CD1 mice were fixed (5% glutaraldehyde, 0.5% PFA, 0.2% Na<sub>2</sub>S<sub>2</sub>O<sub>5</sub>, 0.1 M Na<sub>2</sub>PO<sub>4</sub> buffer at pH 7.4) for 24 h and cryopreserved in 30% sucrose. Tissue was then snap-frozen in liquid nitrogen cooled n-hexane and cut into 30 µm sections. Slices were reduced for 20 min at room temperature in 0.2% Na<sub>2</sub>S<sub>2</sub>O<sub>5</sub> and 0.5% NaBH<sub>4</sub> in 0.1 M Tris-buffered saline (TBS; pH 7.4) and rinsed with 0.2% Na<sub>2</sub>S<sub>2</sub>O<sub>5</sub> in TBS for 45 min. Tissue was blocked in 4% goat serum, 0.2% Triton X-100, and 0.2% Na<sub>2</sub>S<sub>2</sub>O<sub>5</sub> in 0.1 M TBS for 2 h and then incubated in 0.1 M TBS (pH 7.2) with 2% goat serum, 0.1% Triton X-100, and primary antibodies: rabbit anti-b-serine (Millipore), mouse anti-GFAP, and *G. simplicifolia* 1 Isolectin B<sub>4</sub> tagged with Alexa Fluor 488 (Invitrogen) for 48 h. Secondary antibodies Alexa Fluor 633 goat anti-rabbit IqG (H+L) (Invitrogen) and Alexa Fluor 568 goat

- Iadecola C (2004) Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 5(5):347–360.
- Filosa JA, et al. (2006) Local potassium signaling couples neuronal activity to vasodilation in the brain. Nat Neurosci 9(11):1397–1403.
- Girouard H, et al. (2010) Astrocytic endfoot Ca2+ and BK channels determine both arteriolar dilation and constriction. Proc Natl Acad Sci USA 107(8):3811–3816.
- Metea MR, Newman EA (2006) Glial cells dilate and constrict blood vessels: A mechanism of neurovascular coupling. J Neurosci 26(11):2862–2870.
- Takano T, et al. (2006) Astrocyte-mediated control of cerebral blood flow. Nat Neurosci 9(2):260–267.
- Mishra A, Hamid A, Newman EA (2011) Oxygen modulation of neurovascular coupling in the retina. Proc Natl Acad Sci USA 108(43):17827–17831.
- Gordon GR, Choi HB, Rungta RL, Ellis-Davies GC, MacVicar BA (2008) Brain metabolism dictates the polarity of astrocyte control over arterioles. *Nature* 456(7223):745–749.
- Mulligan SJ, MacVicar BA (2004) Calcium transients in astrocyte endfeet cause cerebrovascular constrictions. *Nature* 431(7005):195–199.
- Busija DW, Leffler CW (1989) Dilator effects of amino acid neurotransmitters on piglet pial arterioles. Am J Physiol 257(4 Pt 2):H1200–H1203.
- Faraci FM, Breese KR (1993) Nitric oxide mediates vasodilatation in response to activation of N-methyl-D-aspartate receptors in brain. Circ Res 72(2):476–480.
- Bhardwaj A, et al. (2000) P-450 epoxygenase and NO synthase inhibitors reduce cerebral blood flow response to N-methyl-D-aspartate. Am J Physiol Heart Circ Physiol 279(4):H1616–H1624.
- 12. Simandle SA, et al. (2005) Piglet pial arteries respond to N-methyl-D-aspartate in vivo but not in vitro. *Microvasc Res* 70(1–2):76–83.
- Iadecola C (1993) Regulation of the cerebral microcirculation during neural activity: Is nitric oxide the missing link? Trends Neurosci 16(6):206–214.
- Fergus A, Lee KS (1997) Regulation of cerebral microvessels by glutamatergic mechanisms. Brain Res 754(1–2):35–45.
- Ma J, Ayata C, Huang PL, Fishman MC, Moskowitz MA (1996) Regional cerebral blood flow response to vibrissal stimulation in mice lacking type I NOS gene expression. *Am J Physiol* 270(3 Pt 2):H1085–H1090.
- Alonso-Galicia M, Hudetz AG, Shen H, Harder DR, Roman RJ (1999) Contribution of 20-HETE to vasodilator actions of nitric oxide in the cerebral microcirculation. *Stroke* 30(12):2727–2734, discussion 2734.
- Liu X, et al. (2008) Interaction of nitric oxide, 20-HETE, and EETs during functional hyperemia in whisker barrel cortex. Am J Physiol Heart Circ Physiol 295(2):H619–H631.
- Ma J, et al. (1996) L-NNA-sensitive regional cerebral blood flow augmentation during hypercapnia in type III NOS mutant mice. Am J Physiol 271(4 Pt 2):H1717–H1719.
- Pereira de Vasconcelos A, Riban V, Wasterlain C, Nehlig A (2006) Role of endothelial nitric oxide synthase in cerebral blood flow changes during kainate seizures: A genetic approach using knockout mice. *Neurobiol Dis* 23(1):219–227.
- Hlatky R, et al. (2003) The role of endothelial nitric oxide synthase in the cerebral hemodynamics after controlled cortical impact injury in mice. J Neurotrauma 20(10): 995–1006.
- Endres M, Laufs U, Liao JK, Moskowitz MA (2004) Targeting eNOS for stroke protection. Trends Neurosci 27(5):283–289.
- Dingledine R, Borges K, Bowie D, Traynelis SF (1999) The glutamate receptor ion channels. *Pharmacol Rev* 51(1):7–61.
- Fadda E, Danysz W, Wroblewski JT, Costa E (1988) Glycine and D-serine increase the affinity of N-methyl-D-aspartate sensitive glutamate binding sites in rat brain synaptic membranes. *Neuropharmacology* 27(11):1183–1185.
- 24. Matsui T, et al. (1995) Functional comparison of D-serine and glycine in rodents: The effect on cloned NMDA receptors and the extracellular concentration. *J Neurochem* 65(1):454–458.
- Shleper M, Kartvelishvily E, Wolosker H (2005) D-serine is the dominant endogenous coagonist for NMDA receptor neurotoxicity in organotypic hippocampal slices. J Neurosci 25(41):9413–9417.

anti-mouse IgG (H+L) (Invitrogen) were used for visualization of D-serine and GFAP. Images were collected with a Zeiss LSM510 laser-scanning microscope.

**Data Analysis.** AUC was calculated from percent vessel relaxation versus time plots. AUC among experimental groups were compared using *t* test for two groups or one-way ANOVA with Student Newman–Keuls post hoc test for three or more groups. The time course of glutamate and D-serine release from slices was analyzed by two-way ANOVA with Bonferroni post hoc tests.

ACKNOWLEDGMENTS. The authors thank Ms. Ayumi Tanaka for SR deletion mouse preparation. Research was supported by an operating grant from the Canadian Institutes of Health Research. J.L.S. was supported by a student award from the Canadian Institutes of Health Research.

- Schell MJ, Molliver ME, Snyder SH (1995) D-serine, an endogenous synaptic modulator: Localization to astrocytes and glutamate-stimulated release. *Proc Natl Acad Sci* USA 92(9):3948–3952.
- Wolosker H, Blackshaw S, Snyder SH (1999) Serine racemase: A glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission. Proc Natl Acad Sci USA 96(23):13409–13414.
- Mothet JP, et al. (2005) Glutamate receptor activation triggers a calcium-dependent and SNARE protein-dependent release of the gliotransmitter D-serine. Proc Natl Acad Sci USA 102(15):5606–5611.
- Panatier A, et al. (2006) Glia-derived D-serine controls NMDA receptor activity and synaptic memory. Cell 125(4):775–784.
- Henneberger C, Papouin T, Oliet SH, Rusakov DA (2010) Long-term potentiation depends on release of D-serine from astrocytes. *Nature* 463(7278):232–236.
- Yang Y, et al. (2003) Contribution of astrocytes to hippocampal long-term potentiation through release of D-serine. Proc Natl Acad Sci USA 100(25):15194–15199.
- LeMaistre JL, et al. (2012) Coactivation of NMDA receptors by glutamate and D-serine induces dilation of isolated middle cerebral arteries. J Cereb Blood Flow Metab 32(3): 537–547.
- Zonta M, et al. (2003) Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation. *Nat Neurosci* 6(1):43–50.
- Martineau M, Galli T, Baux G, Mothet JP (2008) Confocal imaging and tracking of the exocytotic routes for D-serine-mediated gliotransmission. *Glia* 56(12):1271–1284.
- Rosenberg D, et al. (2010) Neuronal release of D-serine: A physiological pathway controlling extracellular D-serine concentration. FASEB J 24(8):2951–2961.
- Roman RJ (2002) P-450 metabolites of arachidonic acid in the control of cardiovascular function. *Physiol Rev* 82(1):131–185.
- Koide M, Bonev AD, Nelson MT, Wellman GC (2012) Inversion of neurovascular coupling by subarachnoid blood depends on large-conductance Ca<sup>2+</sup>-activated K<sup>+</sup> (BK) channels. *Proc Natl Acad Sci USA* 109(21):E1387–E1395.
- Tong XK, Hamel E (2000) Basal forebrain nitric oxide synthase (NOS)-containing neurons project to microvessels and NOS neurons in the rat neocortex: Cellular basis for cortical blood flow regulation. *Eur J Neurosci* 12(8):2769–2780.
- Bari F, Errico RA, Louis TM, Busija DW (1996) Interaction between ATP-sensitive K<sup>+</sup> channels and nitric oxide on pial arterioles in piglets. J Cereb Blood Flow Metab 16(6): 1158–1164.
- Meng W, Tobin JR, Busija DW (1995) Glutamate-induced cerebral vasodilation is mediated by nitric oxide through N-methyl-D-aspartate receptors. *Stroke* 26(5): 857–862, discussion 863.
- Faraci FM, Brian JE, Jr. (1995) 7-Nitroindazole inhibits brain nitric oxide synthase and cerebral vasodilatation in response to N-methyl-D-aspartate. *Stroke* 26(11):2172–2175, discussion 2176.
- Chinellato A, Froldi G, Caparrotta L, Ragazzi E (1998) Pharmacological characterization of endothelial cell nitric oxide synthase inhibitors in isolated rabbit aorta. *Life Sci* 62(6):479–490.
- Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S (1990) Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 101(3):746–752.
- 44. de Labra C, et al. (2009) Different sources of nitric oxide mediate neurovascular coupling in the lateral geniculate nucleus of the cat. Front Syst Neurosci 3:9.
- Miya K, et al. (2008) Serine racemase is predominantly localized in neurons in mouse brain. J Comp Neurol 510(6):641–654.
- Wolosker H, et al. (1999) Purification of serine racemase: Biosynthesis of the neuromodulator D-serine. Proc Natl Acad Sci USA 96(2):721–725.
- 47. Zhuang Z, et al. (2010) EphrinBs regulate D-serine synthesis and release in astrocytes. *J Neurosci* 30(47):16015–16024.